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The non-stcroidal nti-inflammatory drug, piroxicam, prevents the hepatic increase of triacylglyccrols and malondialdchyde r sulting front the acute 
ictoxication or rats with ethanol. In addition, in the intoxicated rats, piroxicam consistently produces a decrease in the levels of blood ethanol in 
comparison with control animals. It is suggested that lhe anti-inflammatory compound stimulates ethanol oxidation, 
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1. INTRODUCTION 
Piroxicam, a non-steroidal anti-inflammatory drug 
(NSAID), administered in rats simultaneously with 
CC14, partially prevented the increases in serum ac- 
tivities of two aminotransferases, maintained liver lipo- 
peroxidation and triacylglycerides (TAG) contents at 
normal values, and attenuated the liver morphological 
changes caused by the hepatotoxic ompound [l]. For 
these reasons we searched for the putative action of 
piroxicam preventing the biochemical alterations 
produced in the whole animal by an extremely common 
hepatotoxic ompound: ethanol. 
2. MATERIALS AND METHODS 
Male Wistar rats (200-225 g) were fasted I6 h before treatment and 
divided into four groups: control, receiving isocaloric amounts of 
glucose (as 40% w/v solution) with regard to the doses of ethanol and 
equivalent amounts of piroxicam vehicle solution; ethanol, receiving 
3 or 5 S of ethanol/kg body weight (as 30% solution) and equivalent 
amounts ofpiroxicam vehicle solution; piroxicam, receiving isocaloric 
amounts ofglucose and piroxicam IO m&t/kg body weight (as 7.5 mg/ml 
in a 25% glycerol/water solution v/v); and ethanol plus piroxicam. 
receiving ethanol 3 or 5 B/kgand piroxicam IO m@kg body weight. The 
administered compounds were given by orogastric via (OGV) unless 
otherwise indicated. In most of the experiments rats were killed by 
decapitation, blood was collected in EDTA and liver samples were 
taken to evaluate TAG, protein and malondialdehyde (MDA). TAG 
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were detcrmincd by the method described by Gottfried et al. [2] di- 
rectly in liver homogenates prepared in double distilled water (l:9, 
w/v). MDA was quantilied by the barbituric acid method 131, modified 
as recommended by Hcrnandez-Munoz ct al. [4]. Protein was dclcr- 
mined by the Bradford colorimctric method [5]. Blood ethanol was 
assayed essentially by the method of Berm and Guttman [6], Hema- 
tocrit was measured with standard clinical laboratory techniques. 
In some cxperimcnts rats were sacrificed 2 h after treatment, 
stomachs were excised and weighed, the content of each stomach was 
carefully recovered with the aid of saline solution in order to measure 
elhanol Sastric content. In another series of experiments, rats were 
maintained after treatment in individual metabolic ages and urine 
was collected to determine thanol concentration. 
Reagents were obtained from Sigma Chemical Co. (St. Louis. MO). 
Ethanol analytical grade was purchased from Baker. Statistical naly- 
sis was performed using Student’s I-Lesl. 
3. RESULTS 
The well known increase in liver TAG content 
produced by ethanol was nearly blocked by piroxicam, 
whereas the NSAID alone exhibited non-significant 
alteration in these TAG (Fig. 1). 
Glucose or piroxicam did not change MDA levels 
used here as an index of hepatic lipoperoxidation, 
ethanol treatment showed a significant increase of 
MDA content between 8 and 12 h after intoxication, 
being maximal at 8 h; piroxicam produced a statistically 
significant diminution of MDA values reached with 
ethanol alone (Fig. 2). 
Since alcohol oxidation is required to augment he 
lipoperoxidation index in liver [73 and since piroxicam 
treatment avoids the increase in MDA promoted by 
ethyl alcohol (Figs. 1 and 2), an inhibition in ethanol 
oxidation and a consequent rise in its blood levels due 
to piroxicam administration could be expected. Never- 
theless, in rats intoxicated with ethanol by OGV, the 
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Fig. 1. Effect of piroxicam on ethanol-promoted lipid accumulation 
in liver. Levels of TAG in the liver of rats at different imes after 
treatment. The dose of ethanol was 5 g/kg of body weight by OGV. 
Piroxicam was administcrecl consecutively to glucose or ethanol and 
by the same route. Range of individual assays (II) from 4 to IS; P 
values comparin& ethanol group vs ethanol -C piroxicam group; *P < 
0.001, **P -z 0.01 and ***p < 0,OS. 
curve of blood ethanol as a function of its administra- 
tion was lowered with piroxicam, either used by OGV 
or intraperitoneal via (IPV) (Fig. 3). This action of piro- 
xicam was also observed when ethyl alcohol, 3 B/kg, was 
provided by IPV (data not shown). 
Ethanol content in the stomachs of rats receiving 5 g 
of ethanol per kg of body weight by OGV 2 h before was 
4.62 f 1.14 mmol/g of stomach (n=4), when ethanol was 
given alone, and it was 6.22 1 1.51 (n=4) when ethanol 
was supplemented with pimxicam; the difference was 
without statistical significance (P < 0.2). Similarly, the 
treatment with piroxicam produced no difference in the 
amount of ethanol eliminated by urine from rats treated 
with 3 g of ethanol per kg of body weight by IPV; i,e. 
6 nmol/h and 5 nmol/h with and without piroxicam, 
respectively. Furthermore, the hematocrit value was the 
same in both groups of animals. 
4. DISCUSSION 
Administration of the NSAID impaired the hepatic 
increase in TAG content and in MDA generation 
promoted by ethanol treatment (Figs. 1 and 2). These 
‘protective’ actions of piroxicam toward alcohol in- 
toxication coincided temporarily with its capacity to 
decrease blood ethanol evels (Fig. 3), which cannot be 
attributed to a delay in alcohol absorption from the 
gastrointestinal tube since the effect was present in 
animals receiving the toxic compound by IPV, and pir- 
oxicam did not modify the rate of absorption of ethanol 
by the stomach. In addition, the NSAID neither stimu- 
lated the elimination of ethanol by the kidney, nor orig- 
inated hemodilution. Therefore, it appears that pirox- 
icam caused an increase in ethanol oxidation probably 
due to an induction in the synthesis of nonspecific 
oxidases, as has been reported, for example, with barbi- 
turates [S]. The activation in ethanol disappearance 
caused by piroxicam contrasted with the reported effect 
of aspirin, the prototype of NSAIDs, decreasing the 
activity of gastric alcoholic dehydrogenase in human 
subjects and in rat models at low ethanol doses [9]. 
DiLuzio and Stege clearly showed that peroxidative 
lipid degradation products formed after ethanol con- 
sumption were markedly reduced when ethanol metab- 
olism was blocked by pyrazole, which diminishes acetal- 
dehyde formation, and were augmented by disulfiram, 
an inhibitor that promotes acetaldehyde accumulation 
[7]. Thus, the increase in ethanol oxidation promoted by 
piroxicam should be accompanied by a similar or higher 
increase in acetaldehyde oxidation (there is a report on 
the induction of cytoplasmic aldehyde dehydrogenase 
by drugs [83) in order to discourage a rise in lipoper- 
oxidation and in turn in MDA levels. 
Some consequences of a piroxicam-mediated lower 
blood ethanol evel might include the diminution of liver 
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Fig. 2. Effect of piroxicam on ethanol-promoted liver peroxidation. Levels of M DA in the liver of rats at dilTerent times after receiving the treatment 
indicated in the figure. Other indications as in Fig. I. tr from 3 to 7. *P c 0.001 comparing ethanol vs, ethanol plus peroxicam. 
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HOURS AFTER ETHANOL TREATMENT 
Fig. 3. Role of piroxicam on time course ethanol evels in blood. All 
animals received 5dkg ethanol by OGV plus: (n-A), 0.1 ml saline 
by OGV; (&--..A), 0. I ml 20 mg/ml piroxicam by OGV: and 20 mg/ml 
piroxicam by IPV, (v..-+). For 2 h t1=8, and tt=S in other data. Other 
indications as in Fig. 1. Values of P arc reported comparing results 
of ethanol vs. ethanol + piroxicam at each of the different imes: P < 
0.001, 8 h OGV. 2 h and IO h IPV; P c 0.01.6 h and 8 h IPV; P c 
0.05, 2 and 4 h OGV, 12 h IPV. 
TAG content (Fig. l), a minor cellular transformation 
to hydroxyethyl free radical [lO,ll] and therefore no 
activation, of lipoperoxidation, and also the reported 
decrease in the duration of hypnosis 1121. Finally, the 
action of piroxicam limitating lipoperoxidation and 
MDA production (Fig. 2) might also be related to the 
reported action of NSAlDs to scavenge, or to inhibit, 
the generation of free radicals [ 13,141. 
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